TG Therapeutics | TGTX - Gross Profit On Sales


TG Therapeutics reported $154.43M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 6.48B 307M Sep/2025
Ardelyx USD 114.37M 8.02M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Curis USD 1.14M 8.86M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Infinity Pharmaceuticals USD 231K 59K Jun/2023
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Novartis USD 10.25B 570M Dec/2025
Novavax USD 125.04M 76.09M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Verastem USD 14.64M 14.1M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025